

Javier Briones Meijide

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8497898/publications.pdf>

Version: 2024-02-01

149
papers

5,199
citations

101384

36
h-index

91712

69
g-index

149
all docs

149
docs citations

149
times ranked

9682
citing authors

#	ARTICLE	IF	CITATIONS
1	Anti-CD47 Antibody Synergizes with Rituximab to Promote Phagocytosis and Eradicate Non-Hodgkin Lymphoma. <i>Cell</i> , 2010, 142, 699-713.	13.5	894
2	Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial. <i>Lancet, The</i> , 2019, 393, 229-240.	6.3	517
3	MYC protein expression and genetic alterations have prognostic impact in patients with diffuse large B-cell lymphoma treated with immunochemotherapy. <i>Haematologica</i> , 2013, 98, 1554-1562.	1.7	196
4	Identification of Leptomeningeal Disease in Aggressive B-Cell Non-Hodgkin's Lymphoma: Improved Sensitivity of Flow Cytometry. <i>Journal of Clinical Oncology</i> , 2009, 27, 1462-1469.	0.8	189
5	Prediction of survival in diffuse large B-cell lymphoma based on the expression of 2 genes reflecting tumor and microenvironment. <i>Blood</i> , 2011, 118, 1350-1358.	0.6	175
6	CAR T-cells targeting FLT3 have potent activity against FLT3 ^{ITD} AML and act synergistically with the FLT3-inhibitor crenolanib. <i>Leukemia</i> , 2018, 32, 1168-1179.	3.3	133
7	MicroRNAs Are Independent Predictors of Outcome in Diffuse Large B-Cell Lymphoma Patients Treated with R-CHOP. <i>Clinical Cancer Research</i> , 2011, 17, 4125-4135.	3.2	126
8	Rapid Engraftment Without Significant Graft-Versus-Host Disease After Allogeneic Transplantation of CD34+ Selected Cells From Peripheral Blood. <i>Blood</i> , 1997, 89, 3967-3973.	0.6	120
9	Fludarabine, Cyclophosphamide, and Mitoxantrone as Initial Therapy of Chronic Lymphocytic Leukemia: High Response Rate and Disease Eradication. <i>Clinical Cancer Research</i> , 2008, 14, 155-161.	3.2	117
10	Frequent severe liver iron overload after stem cell transplantation and its possible association with invasive aspergillosis. <i>Bone Marrow Transplantation</i> , 2004, 34, 505-509.	1.3	116
11	Prospective phase II trial of extended treatment with rituximab in patients with B-cell post-transplant lymphoproliferative disease. <i>Haematologica</i> , 2007, 92, 1489-1494.	1.7	116
12	Iron overload might increase transplant-related mortality in haematopoietic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2002, 29, 987-989.	1.3	111
13	BLYS and BLYS receptor expression in non-Hodgkin's lymphoma. <i>Experimental Hematology</i> , 2002, 30, 135-141.	0.2	102
14	Paraffin-based 6-gene model predicts outcome in diffuse large B-cell lymphoma patients treated with R-CHOP. <i>Blood</i> , 2008, 111, 5509-5514.	0.6	93
15	Early and Late Neurological Complications after Reduced-Intensity Conditioning Allogeneic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2009, 15, 1439-1446.	2.0	79
16	Real-world evidence of tisagenlecleucel for the treatment of relapsed or refractory large B-cell lymphoma. <i>Cancer Medicine</i> , 2021, 10, 3214-3223.	1.3	73
17	High-Titer Retroviral Vectors Containing the Enhanced Green Fluorescent Protein Gene for Efficient Expression in Hematopoietic Cells. <i>Blood</i> , 1997, 90, 3316-3321.	0.6	70
18	Conventional versus reduced-intensity conditioning regimen for allogeneic stem cell transplantation in patients with hematological malignancies. <i>European Journal of Haematology</i> , 2005, 74, 144-151.	1.1	68

#	ARTICLE	IF	CITATIONS
19	Comparison of Two Pretransplant Predictive Models and a Flexible HCT-CI Using Different Cut off Points to Determine Low-, Intermediate-, and High-Risk Groups: The Flexible HCT-CI Is the Best Predictor of NRM and OS in a Population of Patients Undergoing allo-RIC. <i>Biology of Blood and Marrow Transplantation</i> , 2010, 16, 413-420.	2.0	67
20	Efficient transduction of human hematopoietic repopulating cells generating stable engraftment of transgene-expressing cells in NOD/SCID mice. <i>Blood</i> , 2000, 95, 3085-3093.	0.6	63
21	NK cells stimulated with IL-15 or CpG ODN enhance rituximab-dependent cellular cytotoxicity against B-cell lymphoma. <i>Experimental Hematology</i> , 2008, 36, 69-77.	0.2	63
22	Early clinical impact of iron overload in stem cell transplantation. A prospective study. <i>Annals of Hematology</i> , 2007, 86, 443-447.	0.8	58
23	Study of Kidney Function Impairment after Reduced-Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplantation. A Single-Center Experience. <i>Biology of Blood and Marrow Transplantation</i> , 2009, 15, 21-29.	2.0	53
24	Lower respiratory tract respiratory virus infections increase the risk of invasive aspergillosis after a reduced-intensity allogeneic hematopoietic SCT. <i>Bone Marrow Transplantation</i> , 2009, 44, 749-756.	1.3	51
25	Multicenter phase II study of plitidepsin in patients with relapsed/refractory non-Hodgkin's lymphoma. <i>Haematologica</i> , 2013, 98, 357-363.	1.7	51
26	Impact of Epstein Barr virus-related complications after high-risk allo-SCT in the era of pre-emptive rituximab. <i>Bone Marrow Transplantation</i> , 2015, 50, 579-584.	1.3	49
27	Patients with biochemical iron overload: causes and characteristics of a cohort of 150 cases. <i>Annals of Hematology</i> , 2003, 82, 127-130.	0.8	46
28	Prognostic indexes in follicular lymphoma: a comparison of different prognostic systems. <i>Annals of Oncology</i> , 2005, 16, 1508-1513.	0.6	46
29	Antitumor Immunity After Vaccination With B Lymphoma Cells Overexpressing a Triad of Costimulatory Molecules. <i>Journal of the National Cancer Institute</i> , 2003, 95, 548-555.	3.0	45
30	Patterns of infection and infection-related mortality in patients with steroid-refractory acute graft versus host disease. <i>Bone Marrow Transplantation</i> , 2017, 52, 107-113.	1.3	45
31	T-Cell Costimulatory Molecules in Acute-Graft-Versus Host Disease: Therapeutic Implications. <i>Bone Marrow Research</i> , 2011, 2011, 1-7.	1.7	44
32	Beta ₂ -microglobulin is a better predictor of treatment-free survival in patients with chronic lymphocytic leukaemia if adjusted according to glomerular filtration rate. <i>British Journal of Haematology</i> , 2009, 145, 801-805.	1.2	41
33	In vivo antitumor effect of CD40L-transduced tumor cells as a vaccine for B-cell lymphoma. <i>Cancer Research</i> , 2002, 62, 3195-9.	0.4	41
34	LITAF, a BCL6 target gene, regulates autophagy in mature B-cell lymphomas. <i>British Journal of Haematology</i> , 2013, 162, 621-630.	1.2	39
35	Lymphoma cell VEGFR2 expression detected by immunohistochemistry predicts poor overall survival in diffuse large B cell lymphoma treated with immunochemotherapy (R-CHOP). <i>British Journal of Haematology</i> , 2010, 148, 235-244.	1.2	38
36	Clinical utility of bone marrow flow cytometry in B-cell non-Hodgkin lymphomas (B-NHL). <i>Histopathology</i> , 2004, 45, 268-274.	1.6	37

#	ARTICLE	IF	CITATIONS
37	Interleukin-15 enhances rituximab-dependent cytotoxicity against chronic lymphocytic leukemia cells and overcomes transforming growth factor beta-mediated immunosuppression. <i>Experimental Hematology</i> , 2011, 39, 1064-1071.	0.2	34
38	Autologous stem cell transplantation after conditioning with yttrium-90 ibritumomab tiuxetan plus BEAM in refractory non-Hodgkin diffuse large B-cell lymphoma: results of a prospective, multicenter, phase II clinical trial. <i>Haematologica</i> , 2014, 99, 505-510.	1.7	34
39	Effects of G-CSF administration and peripheral blood progenitor cell collection in 20 healthy donors. <i>Annals of Hematology</i> , 1996, 72, 269-272.	0.8	31
40	Encouraging Results with Inolimomab (Anti-IL-2 Receptor) as Treatment for Refractory Acute Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2006, 12, 1135-1141.	2.0	30
41	PET/CT Assessment of Follicular Lymphoma and High Grade B Cell Lymphoma - Good Correlation with Clinical and Histological Features at Diagnosis. <i>Advances in Clinical and Experimental Medicine</i> , 2015, 24, 325-330.	0.6	30
42	Membrane PKC-beta 2 protein expression predicts for poor response to chemotherapy and survival in patients with diffuse large B-cell lymphoma. <i>Annals of Hematology</i> , 2006, 85, 597-603.	0.8	28
43	Role of the STAT1 pathway in apoptosis induced by fludarabine and JAK kinase inhibitors in B-cell chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2005, 46, 435-442.	0.6	27
44	Reduced-Intensity Conditioning Allogeneic Blood Stem Cell Transplantation with Fludarabine and Oral Busulfan with or without Pharmacokinetically Targeted Busulfan Dosing in Patients with Myeloid Leukemia Ineligible for Conventional Conditioning. <i>Biology of Blood and Marrow Transplantation</i> , 2005, 11, 437-447.	2.0	26
45	Activation-associated phenotype of CD3+ T cells in acute graft-versus-host disease. <i>Clinical and Experimental Immunology</i> , 2006, 145, 36-43.	1.1	26
46	Activation of the NF- κ B signalling pathway in diffuse large B-cell lymphoma: clinical implications. <i>Histopathology</i> , 2008, 53, 441-449.	1.6	24
47	High clinical and molecular response rates with fludarabine, cyclophosphamide and mitoxantrone in previously untreated patients with advanced stage follicular lymphoma. <i>Haematologica</i> , 2008, 93, 207-214.	1.7	24
48	CD34+-enriched/CD19+-depleted autologous peripheral blood stem cell transplantation for chronic lymphoproliferative disorders. <i>Experimental Hematology</i> , 2002, 30, 824-830.	0.2	23
49	Pulmonary function testing prior to reduced intensity conditioning allogeneic stem cell transplantation in an unselected patient cohort predicts posttransplantation pulmonary complications and outcome. <i>American Journal of Hematology</i> , 2012, 87, 9-14.	2.0	23
50	Strategies to reduce transplant-related mortality after allogeneic stem cell transplantation in elderly patients: Comparison of reduced-intensity conditioning and unmanipulated peripheral blood stem cells vs a myeloablative regimen and CD34+ cell selection. <i>Experimental Hematology</i> , 2003, 31, 1039-1043.	0.2	21
51	A First-in-Human Study of YTB323, a Novel, Autologous CD19-Directed CAR-T Cell Therapy Manufactured Using the Novel T-Charge TM platform, for the Treatment of Patients (Pts) with Relapsed/Refractory (r/r) Diffuse Large B-Cell Lymphoma (DLBCL). <i>Blood</i> , 2021, 138, 740-740.	0.6	21
52	Bcl-10 protein highly correlates with the expression of phosphorylated p65 NF- κ B in peripheral T-cell lymphomas and is associated with clinical outcome. <i>Histopathology</i> , 2009, 54, 478-485.	1.6	20
53	Dendritic and tumor cell fusions transduced with adenovirus encoding CD40L eradicate B-cell lymphoma and induce a Th17-type response. <i>Gene Therapy</i> , 2010, 17, 469-477.	2.3	20
54	Degree of mucositis and duration of neutropenia are the major risk factors for early posttransplant febrile neutropenia and severe bacterial infections after reduced-intensity conditioning. <i>European Journal of Haematology</i> , 2012, 88, 46-51.	1.1	20

#	ARTICLE	IF	CITATIONS
55	A Randomized Phase II Study Comparing Consolidation With a Single Dose Of 90y Ibritumomab Tiuxetan (Zevalin®) (Z) Vs. Maintenance With Rituximab (R) For Two Years In Patients With Newly Diagnosed Follicular Lymphoma (FL) Responding To R-CHOP. Preliminary Results At 36 Months From Randomization. <i>Blood</i> , 2013, 122, 369-369.	0.6	20
56	Low transplant related mortality in older patients with hematologic malignancies undergoing autologous stem cell transplantation. <i>Haematologica</i> , 2003, 88, 300-5.	1.7	20
57	Does reduced-intensity allogeneic transplantation confer a survival advantage to patients with poor prognosis chronic lymphocytic leukaemia? A caseâ€control retrospective analysis. <i>Annals of Oncology</i> , 2009, 20, 2007-2012.	0.6	19
58	Incorporating posttransplant cyclophosphamide-based prophylaxis as standard-of-care outside the haploidentical setting: challenges and review of the literature. <i>Bone Marrow Transplantation</i> , 2020, 55, 1041-1049.	1.3	19
59	Reduction of infection-related mortality after allogeneic PBSCT from HLA-identical siblings: longitudinal analysis from 1994 to 2008 at a single institution. <i>Bone Marrow Transplantation</i> , 2011, 46, 690-701.	1.3	18
60	Memory stem T cells modified with a redesigned CD30â€chimeric antigen receptor show an enhanced antitumor effect in Hodgkin lymphoma. <i>Clinical and Translational Immunology</i> , 2021, 10, e1268.	1.7	18
61	Phase 1b study of the BET protein inhibitor RO6870810 with venetoclax and rituximab in patients with diffuse large B-cell lymphoma. <i>Blood Advances</i> , 2021, 5, 4762-4770.	2.5	17
62	Study of hematopoietic chimerism following allogeneic peripheral blood stem cell transplantation using PCR amplification of short tandem repeats. <i>Annals of Hematology</i> , 1996, 72, 265-268.	0.8	16
63	Impact of Cyclosporine Levels on the Development of Acute Graft versus Host Disease after Reduced Intensity Conditioning Allogeneic Stem Cell Transplantation. <i>Mediators of Inflammation</i> , 2014, 2014, 1-7.	1.4	16
64	Dendritic cells combined with tumor cells and Î±-galactosylceramide induce a potent, therapeutic and NK-cell dependent antitumor immunity in B cell lymphoma. <i>Journal of Translational Medicine</i> , 2017, 15, 115.	1.8	16
65	Polatuzumab vedotin plus obinutuzumab and lenalidomide in patients with relapsed or refractory follicular lymphoma: a cohort of a multicentre, single-arm, phase 1b/2 study. <i>Lancet Haematology</i> , 2021, 8, e891-e901.	2.2	15
66	Emerging therapies for patients with advanced chronic lymphocytic leukaemia. <i>Blood Reviews</i> , 2009, 23, 217-224.	2.8	14
67	Epidemiology of lymphoid malignancies: last decade update. <i>SpringerPlus</i> , 2013, 2, 70.	1.2	14
68	Bendamustine as part of conditioning of autologous stem cell transplantation in patients with aggressive lymphoma: a phase 2 study from the GELTAMO group. <i>British Journal of Haematology</i> , 2019, 184, 797-807.	1.2	13
69	Efficient transduction of human hematopoietic repopulating cells generating stable engraftment of transgene-expressing cells in NOD/SCID mice. <i>Blood</i> , 2000, 95, 3085-3093.	0.6	13
70	Hypercalcemia in a Patient with Chronic Lymphocytic Leukemia Evolving into Richter's Syndrome. <i>Leukemia and Lymphoma</i> , 1996, 21, 521-523.	0.6	12
71	Phase II trial of ofatumumab plus ESHAP (ESHAP) as salvage treatment for patients with relapsed or refractory classical Hodgkin lymphoma after first-line chemotherapy. <i>British Journal of Haematology</i> , 2016, 174, 859-867.	1.2	12
72	Do Patients and Physicians Agree When They Assess Quality of Life?. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1005-1010.	2.0	12

#	ARTICLE	IF	CITATIONS
73	Phase II Study of Yttrium-90-Ibritumomab Tiuxetan as Part of Reduced-Intensity Conditioning (with) Tj ETQq1 1 0.784314 rgBT /Overl Aggressive B Cell Lymphoma: A GELTAMO Trial. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 53-59.	2.0	12
74	Polatuzumab Vedotin Plus Obinutuzumab and Lenalidomide in Patients With Relapsed/Refractory Follicular Lymphoma: Primary Analysis of the Full Efficacy Population in a Phase Ib/II Trial. <i>Blood</i> , 2019, 134, 126-126.	0.6	12
75	Updated Experience with Inolimomab as Treatment for Corticosteroid-Refractory Acute Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 435-439.	2.0	11
76	Long-term follow-up of a prospective phase 2 clinical trial of extended treatment with rituximab in patients with B cell post-transplant lymphoproliferative disease and validation in real world patients. <i>Annals of Hematology</i> , 2021, 100, 1023-1029.	0.8	10
77	Efficacy and Safety of Ruxolitinib in Steroid-Refractory/Dependent Chronic Graft-versus-Host Disease: Real-World Data and Challenges. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 43.e1-43.e5.	0.6	10
78	Emerging therapies for B-cell non-Hodgkin lymphoma. <i>Expert Review of Anticancer Therapy</i> , 2009, 9, 1305-1316.	1.1	9
79	Focal adhesion protein expression in human diffuse large B-cell lymphoma. <i>Histopathology</i> , 2014, 65, 119-131.	1.6	9
80	Total body-surface area as a new prognostic variable in mycosis fungoides and SÅ©zary syndrome. <i>Leukemia and Lymphoma</i> , 2016, 57, 1060-1066.	0.6	9
81	Safety and efficacy of low-dose amphotericin B lipid complex for empirical antifungal therapy of neutropenic fever in patients with hematologic malignancies. <i>Methods and Findings in Experimental and Clinical Pharmacology</i> , 2001, 23, 505.	0.8	9
82	Autologous stem cell transplantation after conditioning with yttrium-90 ibritumomab tiuxetan BEAM in refractory non-Hodgkin diffuse large B-cell lymphoma: results of a prospective, multicenter, phase II clinical trial. <i>Haematologica</i> , 2014, 99, e126-e126.	1.7	8
83	Phase 1/2 study of intratumoral G100 (TLR4 agonist) with or without pembrolizumab in follicular lymphoma. <i>Leukemia and Lymphoma</i> , 2022, 63, 821-833.	0.6	8
84	The use of tetradecanoylphorbol acetate-estmulated peripheral blood cells enhances the prognostic value of interphase fluorescence in situ hybridization in patients with chronic lymphocytic leukemia. <i>Genes Chromosomes and Cancer</i> , 2010, 49, 327-332.	1.5	7
85	Targeted therapy of BCL6-dependent diffuse large B-cell lymphomas by heat-shock protein 90 inhibition. <i>Expert Review of Hematology</i> , 2010, 3, 157-159.	1.0	7
86	Long-term safety and outcome of fludarabine, cyclophosphamide and mitoxantrone (FCM) regimen in previously untreated patients with advanced follicular lymphoma: 12Åyears follow-up of a phase 2 trial. <i>Annals of Hematology</i> , 2017, 96, 639-646.	0.8	7
87	When an HLA identical donor is not available in adults with hematological neoplasms: single-center comparison of single-unit cord blood transplantation and haploidentical-related PBSC transplantation with PTCy using a standardized conditioning platform (thiotepa-busulfan-fludarabine). <i>Annals of Hematology</i> , 2020, 99, 157-165.	0.8	7
88	International and Italian prognostic indices in follicular lymphoma. <i>Haematologica</i> , 2003, 88, 700-4.	1.7	7
89	Mobilization kinetics of peripheral blood progenitor cells after IAPVP-16 salvage chemotherapy plus G-CSF in lymphoproliferative disorders. <i>Bone Marrow Transplantation</i> , 2000, 26, 127-132.	1.3	6
90	Heat-shock proteins: a c-Myc lymphoma target?. <i>Blood</i> , 2015, 125, 1685-1686.	0.6	6

#	ARTICLE	IF	CITATIONS
91	Long-Term Follow-Up of a Phase II Trial of Six Cycles of Dose-Dense R-CHOP-14 for First-Line Treatment of Diffuse Large B-Cell Lymphoma in Young and Elderly Patients. <i>Acta Haematologica</i> , 2016, 136, 76-84.	0.7	6
92	Alemtuzumab treatment for SÅ©zary syndrome: A single-center experience. <i>Journal of Dermatological Treatment</i> , 2016, 27, 179-181.	1.1	6
93	Using the Lymph2Cx assay for assessing cell-of-origin subtypes of HIV-related diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2019, 60, 1087-1091.	0.6	6
94	Assessment of Confirmed Clinical Hypersensitivity to Rituximab in Patients Affected with B-Cell Neoplasia. <i>Advances in Hematology</i> , 2020, 2020, 1-5.	0.6	6
95	The outcome of patients with Hodgkin lymphoma and early relapse after autologous stem cell transplant has improved in recent years. <i>Leukemia</i> , 2022, 36, 1646-1653.	3.3	6
96	Demonstration of donor origin of CD34+ HLA-DR~ bone marrow cells after allogeneic peripheral blood transplantation with a long follow-up. <i>Bone Marrow Transplantation</i> , 1998, 21, 189-194.	1.3	5
97	New therapies in non-Hodgkin lymphoma. <i>Expert Review of Anticancer Therapy</i> , 2015, 15, 349-359.	1.1	5
98	The novel agonistic iNKT-cell antibody NKT14m induces a therapeutic antitumor response against B-cell lymphoma. <i>Oncolmmunology</i> , 2019, 8, e1546543.	2.1	5
99	Efficacy and safety assessment of prolonged maintenance with subcutaneous rituximab in patients with relapsed or refractory indolent non-Hodgkin lymphoma: results of the phase III MabCute study. <i>Haematologica</i> , 2022, 107, 500-509.	1.7	5
100	A randomized phase II study comparing consolidation with a single dose of ⁹⁰Y ibritumomab tiuxetan <i>vs.</i> maintenance with rituximab for two years in patients with newly diagnosed follicular lymphoma responding to R-CHOP. Long-term follow-up results. <i>Leukemia and Lymphoma</i> , 2022, 63, 93-100.	0.6	5
101	Polatuzumab vedotin (Pola) + obinutuzumab (G) and lenalidomide (Len) in patients (pts) with relapsed/refractory (R/R) follicular lymphoma (FL): Interim analysis of a phase Ib/II trial.. <i>Journal of Clinical Oncology</i> , 2019, 37, 7505-7505.	0.8	5
102	Therapeutic vaccines for non-Hodgkin B-cell lymphoma. <i>Clinical and Translational Oncology</i> , 2008, 10, 543-551.	1.2	4
103	Reduced-intensity conditioning allogeneic hematopoietic cell transplantation using oral fludarabine as part of the conditioning regimen. <i>Cytotherapy</i> , 2009, 11, 356-361.	0.3	4
104	Discussion on the indication of allogeneic stem cell transplantation for advanced cutaneous T cell lymphomas. <i>International Journal of Hematology</i> , 2019, 110, 406-410.	0.7	4
105	Silent T-cell receptor cutaneous T-cell lymphoma associated to a clonal plasma cell proliferation. <i>Hematology Reports</i> , 2019, 11, 7841.	0.3	4
106	Immune~based Therapies for Hematological Malignancies: An Update by the EHA SWG on Immunotherapy of Hematological Malignancies. <i>HemaSphere</i> , 2020, 4, e423.	1.2	4
107	Long Term Follow-up of a Phase 2 Study Examining Intratumoral G100 Alone and in Combination with Pembrolizumab in Patients with Follicular Lymphoma. <i>Blood</i> , 2018, 132, 2892-2892.	0.6	4
108	Real-World Evidence of Tisagenlecleucel for the Treatment of Relapsed or Refractory Large B-Cell Lymphoma. <i>Blood</i> , 2020, 136, 19-21.	0.6	4

#	ARTICLE	IF	CITATIONS
109	Revised International Prognostic Index and genetic alterations are associated with early failure to R-CHOP in patients with diffuse large B-cell lymphoma. <i>British Journal of Haematology</i> , 2022, 196, 589-598.	1.2	4
110	Results from a phase 1b study of blinatumomab-pembrolizumab combination in adults with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL). <i>Journal of Clinical Oncology</i> , 2022, 40, e19584-e19584.	0.8	4
111	Allogeneic hematopoietic stem cell transplantation for non-Hodgkin's lymphomas: a retrospective analysis of 77 cases. <i>Annals of Hematology</i> , 2017, 96, 787-796.	0.8	3
112	Evolution of Outcome over Time for Relapsed Hodgkin Lymphoma after Autologous Stem Cell Transplant: Improved Survival for Early Relapse in Recent Years. <i>Blood</i> , 2020, 136, 9-10.	0.6	3
113	A Randomized Comparison Of Maintenance Therapy With Subcutaneous Rituximab For 2 Years Versus Until Progression In Patients With Indolent Non-Hodgkin's Lymphoma: Interim Safety Data From The Mabcute Study. <i>Blood</i> , 2013, 122, 3052-3052.	0.6	3
114	Allogeneic transplants with peripheral blood progenitor cells: a report of six cases. <i>Leukemia and Lymphoma</i> , 1996, 20, 471-474.	0.6	2
115	The EHA Research Roadmap: Immune-based Therapies for Hematological Malignancies. <i>HemaSphere</i> , 2021, 5, e642.	1.2	2
116	Plitidepsin Is Active in Peripheral T-Cell Lymphoma (PTCL): A Subset Analysis from An Ongoing Multicenter Phase II Trial. <i>Blood</i> , 2008, 112, 1566-1566.	0.6	2
117	Validation of Comorbidity Indexes in Reduced-Intensity Conditioning (RIC) Allogeneic Stem Cell Transplantation. the Hematopoietic Cell Transplantation Comorbidity Index Is the Best Predictor of NRM and Survival. <i>Blood</i> , 2008, 112, 3277-3277.	0.6	2
118	Autologous Stem Cell Transplantation with Yttrium-90-Ibritumomab Tiuxetan (Zevalin) Plus BEAM Conditioning in Patients with Refractory Non-Hodgkin Diffuse Large B-Cell Lymphoma: Results of a Prospective, Multicenter, Phase II Clinical Trial. <i>Blood</i> , 2012, 120, 1978-1978.	0.6	2
119	Myeloablative Versus Reduced Intensity Allogeneic Stem Cell Transplantation in Relapsed Hodgkin's Lymphoma in Recent Years. a Retrospective Analysis of the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. <i>Blood</i> , 2014, 124, 2562-2562.	0.6	2
120	Intratumoral G100 to induce systemic immune responses and abscopal tumor regression in patients with follicular lymphoma. <i>Journal of Clinical Oncology</i> , 2017, 35, 7537-7537.	0.8	2
121	Prediction of Survival in Diffuse Large B-Cell Lymphoma Based On the Expression of Two Genes: Integration of Tumor and Microenvironment Contributions. <i>Blood</i> , 2009, 114, 622-622.	0.6	2
122	Fludarabine-Induced Apoptosis in CD19+/?/CD5+ B-CLL Cells is a Direct and Nurse-Like-Cell Independent Effect. <i>Leukemia and Lymphoma</i> , 2004, 45, 2307-2314.	0.6	1
123	Chronic Lymphocytic Leukemia: Clinical Stages Maintain Their Prognostic Significance Over the Course of the Disease and Are Surrogates for Response to Therapy. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, 737-742.	0.2	1
124	Reference values for the EORTC QLQ-C30 in patients with advanced stage Hodgkin lymphoma and in Hodgkin lymphoma survivors. <i>European Journal of Haematology</i> , 2021, 106, 697-707.	1.1	1
125	Paraffin-Based 6-Gene Model Predicts Outcome of Diffuse Large B-Cell Lymphoma Patients Treated with R-CHOP. <i>Blood</i> , 2007, 110, 49-49.	0.6	1
126	Efficacy and Safety Of Temozolomide In Patients With Relapsed Or Refractory Mantle Cell Lymphoma: Results From The Spanish Experience. <i>Blood</i> , 2013, 122, 5117-5117.	0.6	1

#	ARTICLE	IF	CITATIONS
127	Axicabtagene Ciloleucef Compared to Tisagenlecleucel for the Treatment of Relapsed or Refractory Large B-Cell Lymphoma in the Real World Setting in Spain. <i>Blood</i> , 2021, 138, 1742-1742.	0.6	1
128	Low Rate of Invasive Fungal Infections During Induction and Consolidation Chemotherapy for Adults with De Novo Acute Myeloid Leukemia Without Anti-mold Prophylaxis: Single-Center 2002-2018 Empirical/Pre-emptive Approach. <i>Mycopathologia</i> , 2020, 185, 639-652.	1.3	0
129	Linfoma no Hodgkin nodal de zona marginal bajo tratamiento anti-TNF en enfermedad de Crohn. <i>Gastroenterología Y Hepatología</i> , 2021, , .	0.2	0
130	Rituximab-Mediated Antibody-Dependent Cellular Cytotoxicity Is Enhanced by Interleukin-15 or CpG Oligodeoxynucleotides.. <i>Blood</i> , 2005, 106, 2440-2440.	0.6	0
131	Long Remission Are Possible after Non Myeloablative Transplant in Patients with Follicular Non-Hodgkin's Lymphoma (NHL): Results of Two Prospectives Multicenter Trials.. <i>Blood</i> , 2006, 108, 3024-3024.	0.6	0
132	Efficacy of Dose-Dense R-CHOP-14 Chemoimmunotherapy Plus Pegfilgrastim for First-Line Treatment of Diffuse Large B-Cell Lymphoma (DLBCL) in Low Risk Patients: An Interim Analysis of an Open-Label Clinical Trial in Spain. On Behalf of GEL/TAMO (Spanish Group of Lymphoma).. <i>Blood</i> , 2007, 110, 3443-3443.	0.6	0
133	Reduced-Intensity Conditioning Allogeneic Hematopoietic Cell Transplantation Using Oral Fludarabine as Part of the Conditioning Regimen.. <i>Blood</i> , 2007, 110, 4925-4925.	0.6	0
134	Comparison of Cyclosporine A and Mycophenolate Mofetil vs Cyclosporine A and Methotrexate in Reduced Intensity Conditioning HLA Sibling Allogeneic Stem Cell Transplantation. A Case-Match Single-Center Experience.. <i>Blood</i> , 2007, 110, 4994-4994.	0.6	0
135	Treatment of Chronic Myeloid Leukemia with Imatinib. A Single Centre Experience. <i>Blood</i> , 2008, 112, 4289-4289.	0.6	0
136	Therapeutic Antimyeloma Effect of Dendritic-Tumor Cells Hybrids Transduced with Adenovirus Encoding CD40L.. <i>Blood</i> , 2008, 112, 1709-1709.	0.6	0
137	Relapse after Autologous Stem Cell Transplant (ASCT) for Diffuse Large B Cell Lymphoma: Clinical Outcome and Prognostic Factors Affecting Long-Term Outcome. <i>Blood</i> , 2008, 112, 2593-2593.	0.6	0
138	Targeting the Poor Mobilizing Population of Patients for An Autologous Transplantation Procedure: A Single Centre Experience. <i>Blood</i> , 2008, 112, 4136-4136.	0.6	0
139	T-Cell Receptor Signaling Proteins, BCL10 and Phosphorylated-P65 NFkB, Are Expressed in Peripheral T-Cell Lymphomas and Associated with Clinical Outcome. <i>Blood</i> , 2008, 112, 2820-2820.	0.6	0
140	The Use of Tetradenoylphorbol Acetate Stimulated Peripheral Blood Cells for Interphase Fluorescence In-Situ Hybridization Analysis May Enhance Its Prognostic Value for Patients with Chronic Lymphocytic Leukemia. <i>Blood</i> , 2008, 112, 4152-4152.	0.6	0
141	Therapeutic Compliance and Efficacy of Dose-Dense R-CHOP-14 Immunochemotherapy Plus Pegfilgrastim for First-Line Treatment of Low Risk Diffuse Large B-Cell Lymphoma Patients: Preliminary Results of An Open-Label Clinical Trial in Spain. <i>Blood</i> , 2008, 112, 4943-4943.	0.6	0
142	MicroRNA Are Useful Biomarkers for Prediction of Response to Therapy and Survival of Patients with Diffuse Large B-Cell Lymphoma.. <i>Blood</i> , 2009, 114, 624-624.	0.6	0
143	Long-Term Follow-Up Of Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation For High Risk Follicular Lymphoma. <i>Blood</i> , 2013, 122, 5519-5519.	0.6	0
144	Cancer Vaccines: Fundamentals and Strategies. <i>Advances in Delivery Science and Technology</i> , 2014, , 163-185.	0.4	0

#	ARTICLE	IF	CITATIONS
145	Autologous Stem Cell Transplantation in Patients with Mantle Cell Lymphoma: A Retrospective Study of the Geltamo Group (1994-2011). <i>Blood</i> , 2014, 124, 3980-3980.	0.6	0
146	Integrating Genomic Alterations in Diffuse Large B-Cell Lymphoma Identifies New Relevant Pathways and Potential Therapeutic Targets. <i>Blood</i> , 2016, 128, 152-152.	0.6	0
147	Management experience of advanced-stage mycosis fungoides/S�azary syndrome: a retrospective study from Spanish haematology referral units. <i>European Journal of Dermatology</i> , 2020, 30, 397-403.	0.3	0
148	Brentuximab Vedotin Plus ESHAP (BRESHAP) Versus ESHAP As Salvage Strategy for Patients with Primary Refractory or Relapsed Classical Hodgkin's Lymphoma. Preliminary Results from the Breselibet Prospective Clinical Trial. <i>Blood</i> , 2021, 138, 2459-2459.	0.6	0
149	CAR-T Cells with High CAR Expression Intensity Have Improved <i>In Vitro</i> and <i>In Vivo</i> Anti-Lymphoma Effect without Functional Exhaustion. <i>Blood</i> , 2020, 136, 34-34.	0.6	0